SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

INSIDE INFORMATION
(1) DELAY IN PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025;
(2) POSTPONEMENT OF BOARD MEETING; AND
(3) POSSIBLE SUSPENSION OF TRADING

This announcement is made by Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) and Rule 13.49(3)(i) of the Rules (the "**Listing Rules**") Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated March 17, 2026 in relation to the meeting ("**Board Meeting**") of the board (the "**Board**") of directors (the "**Directors**") of the Company to be held on March 27, 2026 for the purposes of, among other matters, considering and approving the annual results of the Group for the year ended December 31, 2025 (the "**2025 Annual Results**") and its publication, considering the payment of a final dividend (if any), and transacting any other business.

DELAY IN PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2025 Annual Results on a date not later than three months after the end of the financial year of the Company, namely, on or before March 31, 2026. Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2025 Annual Results shall be based on the Company's financial statements for the financial year ended December 31, 2025, which shall be agreed with the Company's auditor.

The Board hereby announces that it was notified by the auditor of the Company (the "**Auditor**") that it was still in the course of collecting the documentation and information to complete the annual audit for the year ended December 31, 2025 (the "**2025 Annual Audit**"), and require additional time and resources to complete the 2025 Annual Audit. Based on the above, the Board foresees that the Company will not be able to publish the 2025 Annual Results as required under Rule 13.49(1) of the Listing Rules.

As of the date of this announcement, the Company is actively cooperating with the Auditor and assisting it to complete the outstanding procedures for 2025 Annual Audit.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results, it must announce its results based on the financial results which have yet to be agreed with the auditor (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended December 31, 2025 at this stage as it may not accurately reflect the financial performance and position of the Group and may create unnecessary confusion to the shareholders and potential investors of the Company.

Further announcement(s) will be made by the Company to inform its shareholders and potential investors of the Company any material developments in connection with the 2025 Annual Results as and when appropriate.

POSTPONEMENT OF BOARD MEETING

Due to the aforesaid delay in the publication of the 2025 Annual Results, the Board Meeting originally scheduled to be held on March 27, 2026, will be postponed to another date to be fixed and announced by the Board.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rules 13.50 of the Listing Rules, if the issuer fails to publish periodic financial information in accordance with the Listing Rules, the Stock Exchange will normally request a suspension of trading in the issuer's securities and the suspension will normally continue until the issuer publishes an announcement containing the requisite financial information. Accordingly, trading in the shares of the Company on the Stock Exchange is currently expected to be suspended with effect from 9:00 a.m. on April 1, 2026 pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, March 27, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.